Aurintricarboxylic acid 

Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC₅₀s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively^[1]. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase^[2]. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis^[3]. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway^[4]. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC₅₀ of 0.6 μM^[5]. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC₅₀ of 0.47 µM^[6].

Aurintricarboxylic acid weakly inhibits P2X2/3Rs, P2X2Rs, P2X4Rs or P2X7Rs^[1].
Aurintricarboxylic acid inhibits ATP-induced currents in a concentration dependent manner^[1].
Aurintricarboxylic acid can inhibit the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and vaccinia virus^[2].
Aurintricarboxylic acid inhibits replication of influenza A and B viruses by inhibition of neuraminidase activities^[2].
Aurintricarboxylic acid inhibits TWEAK-Fn14-mediated NF-κB activation^[4].
Aurintricarboxylic acid (10 μM; 0.5-2 hours) suppresses TWEAK-Fn14-mediated NF-κB, Akt, and Src phosphorylation in GBM cells^[4].
Aurintricarboxylic acid represses TWEAK-stimulated glioma cell migration and invasion without causing cell cytotoxicity^[4].
Aurintricarboxylic acid (Compound 8) cannot regulate loading of endogenous let-7 onto AGO2 inside cultured cells, whereas can inhibit RISC loading of exogenous siRNA^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

422.34

Solid

C₂₂H₁₄O₉

4431-00-9

O=C(C=C/1)C(C(O)=O)=CC1=C(C2=CC(C(O)=O)=C(O)C=C2)\C3=CC(C(O)=O)=C(O)C=C3

Room temperature in continental US; may vary elsewhere.

• [1]. Obrecht AS, et al. Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors. Neuropharmacology. 2019 Nov 1;158:107749.  [Content Brief]

  [2]. Hashem AM, et al. Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases. PLoS One. 2009 Dec 17;4(12):e8350.  [Content Brief]

  [3]. Benchokroun Y, et al. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochem Pharmacol. 1995 Jan 31;49(3):305-13.  [Content Brief]

  [4]. Alison Roos, et al. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Oncotarget. 2017 Feb 14; 8(7): 12234–12246.  [Content Brief]

  [5]. Youtian Hu, et al. Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase. J Med Chem. 2019 Feb 14;62(3):1677-1683.  [Content Brief]

  [6]. Rengen Fan, et al. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biol. 2019 Jun; 16(6): 707-718.  [Content Brief]